Drug Approval | May 04, 2022
Eugia Pharma receives USFDA approval for Bortezomib
The approved product has a market size of US $ 1172 million for the twelve months ending March 2022, according to IQVIA
The approved product has a market size of US $ 1172 million for the twelve months ending March 2022, according to IQVIA
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
As a global mushroom biotechnology group, Mycelium Biotechnology is engaged in mushroom growing, global distribution and offering biotechnology and nutraceutical solutions through global partners
The announcement follows FDA 510(k) clearance of device
Three RFPs now open for qualified researchers through NORD's Jayne Holtzer rare disease research grants program
Avacc 3 has significant advantages over existing whooping cough vaccines
Blood test for early detection of Alzheimer's Disease (AD) risk will lead to better patient care, physicians say; US. adults call for earlier evaluation and more education
Move brings together AstraZeneca and Alexion colleagues in a purpose-built facility in Kendall Square, Cambridge, MA, a world-leading life sciences hub
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
Subscribe To Our Newsletter & Stay Updated
